MX2010008466A - Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. - Google Patents
Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.Info
- Publication number
- MX2010008466A MX2010008466A MX2010008466A MX2010008466A MX2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A
- Authority
- MX
- Mexico
- Prior art keywords
- modified release
- coa reductase
- reductase inhibitors
- hmg coa
- release formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 102000004316 Oxidoreductases Human genes 0.000 abstract 1
- 108090000854 Oxidoreductases Proteins 0.000 abstract 1
- 206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 231100000417 nephrotoxicity Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN145KO2008 | 2008-01-30 | ||
| PCT/IN2009/000069 WO2009095934A1 (en) | 2008-01-30 | 2009-01-30 | Modified release formulations of hmg coa reductase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010008466A true MX2010008466A (es) | 2010-10-25 |
Family
ID=40638221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010008466A MX2010008466A (es) | 2008-01-30 | 2009-01-30 | Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110003837A1 (https=) |
| EP (1) | EP2285353A1 (https=) |
| JP (1) | JP2011510974A (https=) |
| AU (1) | AU2009208610A1 (https=) |
| BR (1) | BRPI0906728A2 (https=) |
| MX (1) | MX2010008466A (https=) |
| WO (1) | WO2009095934A1 (https=) |
| ZA (1) | ZA201006157B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590161B2 (en) * | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642268B2 (en) * | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| IL149422A0 (en) * | 1999-11-03 | 2002-11-10 | Smith Howard J & Ass Pty Ltd | Oral pharmaceutical compositions for liver therapy |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| DE10209979A1 (de) * | 2002-03-07 | 2003-09-25 | Ratiopharm Gmbh | Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| US20050147620A1 (en) * | 2004-01-05 | 2005-07-07 | Karl Bozicevic | Cinnamon formulation for reducing cholesterol and/or glucose levels |
| EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
-
2009
- 2009-01-30 AU AU2009208610A patent/AU2009208610A1/en not_active Abandoned
- 2009-01-30 EP EP09706394A patent/EP2285353A1/en not_active Withdrawn
- 2009-01-30 JP JP2010544844A patent/JP2011510974A/ja active Pending
- 2009-01-30 WO PCT/IN2009/000069 patent/WO2009095934A1/en not_active Ceased
- 2009-01-30 MX MX2010008466A patent/MX2010008466A/es not_active Application Discontinuation
- 2009-01-30 US US12/865,448 patent/US20110003837A1/en not_active Abandoned
- 2009-01-30 BR BRPI0906728-0A patent/BRPI0906728A2/pt not_active IP Right Cessation
-
2010
- 2010-08-27 ZA ZA2010/06157A patent/ZA201006157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011510974A (ja) | 2011-04-07 |
| US20110003837A1 (en) | 2011-01-06 |
| AU2009208610A1 (en) | 2009-08-06 |
| BRPI0906728A2 (pt) | 2015-07-07 |
| WO2009095934A1 (en) | 2009-08-06 |
| EP2285353A1 (en) | 2011-02-23 |
| ZA201006157B (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008010921A3 (en) | Modulators of pharmacokinetic properties of therapeutics | |
| GB2448224B (en) | Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent | |
| PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
| WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
| WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
| JOP20080499B1 (ar) | تراكيب صيدلية تعتمد على هيكليات فوقية للمواد المضادة لمستقبلات الانجيوتنسين ومثبطات الاندوبيبتيداز المتعادلة | |
| WO2008067257A3 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
| IL197574A0 (en) | Pharmaceutical compositions | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| MA34313B1 (fr) | Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan | |
| WO2007100614A3 (en) | STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR | |
| WO2008062476A3 (en) | Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof | |
| PL1718288T3 (pl) | Stałe preparaty ospemifenu | |
| WO2008008660A3 (en) | Cyclopentane derivatives as antiglaucoma agents | |
| TNSN06220A1 (en) | Benzimidazole derivatives | |
| WO2006091575A3 (en) | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts | |
| MX342041B (es) | Formulacion farmaceutica para inhibidores de histona desacetilasa. | |
| WO2010137040A3 (en) | Novel pharmaceutical compositions of ranolazine | |
| MX2010008466A (es) | Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. | |
| WO2005123049A3 (en) | A pharmaceutical composition for increasing the mitochondrial genesis | |
| WO2008057464A3 (en) | Compositions and methods for improving the bioavailability of liothyronine | |
| IN2014CN02343A (en) | Oral formulations containing hyaluronic acid for sustained drug release | |
| WO2008099781A1 (ja) | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |